Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVXNASDAQ:ATOSNASDAQ:PGENNASDAQ:SAGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXABIVAX Société Anonyme$5.96+4.8%$6.28$4.77▼$14.71$378.21M0.29140,957 shs65,195 shsATOSAtossa Therapeutics$0.79-2.6%$0.75$0.55▼$1.66$102.30M1.01779,835 shs225,742 shsPGENPrecigen$1.42+3.3%$1.43$0.65▼$2.17$417.68M1.821.33 million shs379,012 shsSAGESage Therapeutics$6.57+1.3%$7.23$4.62▼$13.47$411.73M0.21.19 million shs57,130 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXABIVAX Société Anonyme-0.18%-2.41%-21.76%-26.14%-58.84%ATOSAtossa Therapeutics-3.19%-6.60%+9.48%+9.15%-42.73%PGENPrecigen-2.84%+3.79%-11.61%-21.71%+0.37%SAGESage Therapeutics-0.61%-4.71%-16.60%-9.87%-45.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABVXABIVAX Société Anonyme2.5227 of 5 stars3.54.00.00.02.20.80.6ATOSAtossa Therapeutics1.573 of 5 stars3.50.00.00.03.21.70.0PGENPrecigen3.659 of 5 stars3.50.00.04.72.51.70.6SAGESage Therapeutics3.769 of 5 stars3.01.00.04.02.91.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXABIVAX Société Anonyme 3.00Buy$31.00441.96% UpsideATOSAtossa Therapeutics 3.00Buy$7.13768.90% UpsidePGENPrecigen 3.00Buy$7.00405.42% UpsideSAGESage Therapeutics 2.06Hold$8.8735.97% UpsideCurrent Analyst Ratings BreakdownLatest ATOS, ABVX, SAGE, and PGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025PGENPrecigenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight4/30/2025ABVXABIVAX Société AnonymeJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$33.00 ➝ $33.004/25/2025SAGESage TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/21/2025ATOSAtossa TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $7.253/26/2025ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/20/2025ABVXABIVAX Société AnonymeMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingEqual Weight$12.003/20/2025PGENPrecigenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/12/2025ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/11/2025SAGESage TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform$5.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXABIVAX Société AnonymeN/AN/AN/AN/A$3.37 per shareN/AATOSAtossa TherapeuticsN/AN/AN/AN/A$0.73 per shareN/APGENPrecigen$4.20M97.32N/AN/A$0.48 per share2.89SAGESage Therapeutics$47.40M8.61N/AN/A$7.56 per share0.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXABIVAX Société Anonyme-$159.90MN/A0.00N/AN/AN/AN/AN/A6/2/2025 (Estimated)ATOSAtossa Therapeutics-$30.09M-$0.21N/AN/AN/AN/A-35.74%-33.51%8/11/2025 (Estimated)PGENPrecigen-$95.90M-$0.56N/AN/AN/A-3,521.68%-123.06%-87.33%8/13/2025 (Estimated)SAGESage Therapeutics-$400.67M-$5.80N/AN/AN/A-971.50%-68.18%-60.84%7/30/2025 (Estimated)Latest ATOS, ABVX, SAGE, and PGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/2/2025N/AABVXABIVAX Société Anonyme-$1.5884N/AN/AN/A$3.11 millionN/A5/14/2025Q1 2025PGENPrecigen-$0.08-$0.07+$0.01-$0.18$0.50 million$1.34 million5/13/2025Q1 2025ATOSAtossa Therapeutics-$0.06-$0.05+$0.01-$0.05N/AN/A4/29/2025Q1 2025SAGESage Therapeutics-$0.99-$1.01-$0.02-$1.01$14.12 million$14.06 million3/25/2025Q4 2024ATOSAtossa Therapeutics-$0.0633-$0.05+$0.0133-$0.05N/AN/A3/19/2025Q4 2024PGENPrecigen-$0.06-$0.04+$0.02-$0.06$1.30 million$1.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVXABIVAX Société AnonymeN/AN/AN/AN/AN/AATOSAtossa TherapeuticsN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/ASAGESage TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXABIVAX Société Anonyme0.483.04N/AATOSAtossa TherapeuticsN/A13.3013.30PGENPrecigenN/A1.631.63SAGESage TherapeuticsN/A7.427.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXABIVAX Société Anonyme47.91%ATOSAtossa Therapeutics12.74%PGENPrecigen33.51%SAGESage Therapeutics99.22%Insider OwnershipCompanyInsider OwnershipABVXABIVAX Société AnonymeN/AATOSAtossa Therapeutics8.70%PGENPrecigen44.90%SAGESage Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXABIVAX Société Anonyme6163.44 millionN/ANot OptionableATOSAtossa Therapeutics8129.17 million116.24 millionOptionablePGENPrecigen190295.18 million161.37 millionOptionableSAGESage Therapeutics69062.62 million58.10 millionOptionableATOS, ABVX, SAGE, and PGEN HeadlinesRecent News About These CompaniesBronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities InvestigationMay 29 at 10:05 AM | accessnewswire.comMan Group plc Takes Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)May 28 at 3:51 AM | marketbeat.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the InvestigationMay 27 at 10:00 AM | accessnewswire.com136,723 Shares in Sage Therapeutics, Inc. (NASDAQ:SAGE) Purchased by Toronto Dominion BankMay 27 at 4:15 AM | marketbeat.comSage Therapeutics, Inc. (NASDAQ:SAGE) Shares Purchased by Millennium Management LLCMay 27 at 3:38 AM | marketbeat.comSage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationMay 25, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Investors to ConnectMay 22, 2025 | accessnewswire.comLazard Asset Management LLC Buys New Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)May 22, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Buys 114,173 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)May 21, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities InvestigationMay 20, 2025 | accessnewswire.comBrokerages Set Sage Therapeutics, Inc. (NASDAQ:SAGE) PT at $8.81May 20, 2025 | americanbankingnews.comSage Therapeutics (NASDAQ:SAGE) Lowered to Sell Rating by StockNews.comMay 20, 2025 | americanbankingnews.comNeuromodulation: rewiring healthcare?May 19, 2025 | msn.comSage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of "Hold" from BrokeragesMay 19, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Reach OutMay 18, 2025 | accessnewswire.comRTW Investments LP Lowers Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)May 18, 2025 | marketbeat.comJane Street Group LLC Raises Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)May 18, 2025 | marketbeat.comCubist Systematic Strategies LLC Acquires Shares of 152,726 Sage Therapeutics, Inc. (NASDAQ:SAGE)May 17, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Reduces Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)May 16, 2025 | marketbeat.comAlgert Global LLC Sells 104,738 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)May 16, 2025 | marketbeat.comSage Therapeutics Shareholder Sues Over Drug Prospect ClaimsMay 16, 2025 | news.bloomberglaw.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATOS, ABVX, SAGE, and PGEN Company DescriptionsABIVAX Société Anonyme NASDAQ:ABVX$5.96 +0.28 (+4.84%) As of 11:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Atossa Therapeutics NASDAQ:ATOS$0.79 -0.02 (-2.61%) As of 11:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Precigen NASDAQ:PGEN$1.42 +0.05 (+3.28%) As of 11:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.Sage Therapeutics NASDAQ:SAGE$6.56 +0.09 (+1.31%) As of 11:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? CrowdStrike Stock Slips: Analyst Downgrades Before Earnings AutoZone Stock to Cross $4400 This Year: This Is Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
